This is an investigational study. Sorafenib is FDA approved and commercially available for use in solid tumors. Its use alone after a stem cell transplant and in combination with busulfan and fludarabine before a stem cell transplant is investigational. Busulfan and fludarabine are FDA approved and commercially available for use in stem cell transplantation.